Evidence map›Paper›PMID 37470942›Full record

SynthesisAdvances in therapy2023

Understanding the Global Burden of Influenza in Adults Aged 18-64 years: A Systematic Literature Review from 2012 to 2022.

Farzaneh Maleki, Verna Welch, Santiago M C Lopez, Alejandro Cane, Jakob Langer, Ashley Enstone, Kristen Markus, Olivia Wright, Nicole Hewitt, Isabelle Whittle

Abstract readSystematic Review
In one paragraph

Synthesis in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Disparities in Seasonal Influenza Vaccination in Europe.Immunity, inflammation and disease · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Farzaneh MalekiPfizer Global Access and Value, Cambridge, MA, USA. Farzaneh.Maleki@pfizer.com.
Verna WelchPfizer Vaccines Medical and Scientific Affairs, Collegeville, PA, USA.
Santiago M C LopezPfizer Vaccines Medical and Scientific Affairs, Collegeville, PA, USA.
Alejandro CanePfizer Vaccines Medical and Scientific Affairs, Collegeville, PA, USA.
Jakob LangerPfizer Global Access and Value, Lisbon, Portugal.
Ashley EnstoneAdelphi Values PROVE, Bollington, SK10 5JB, UK.
Kristen MarkusAdelphi Values PROVE, Bollington, SK10 5JB, UK.
Olivia WrightAdelphi Values PROVE, Bollington, SK10 5JB, UK.
Nicole HewittAdelphi Values PROVE, Bollington, SK10 5JB, UK.
Isabelle WhittleAdelphi Values PROVE, Bollington, SK10 5JB, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAdults aged 18-64 years comprise most of the working population, meaning that influenza infection can be disruptive, causing prolonged absence from the workplace, and reduced productivity and the ability to care for dependents. Influenza vaccine uptake is relatively low, even among the older adults in this population (i.e., aged 50-64 years), reflecting a lack of perceived need for vaccination. This systematic literature review (SLR) aimed to characterize the global burden of influenza in the 18-64 years population.

methodsAn electronic database search was conducted and supplemented with conference and gray literature searches. Eligible studies described at least one of clinical, humanistic, or economic outcomes in adults aged 18-64 years and conducted across several global regions. Included studies were published in English, between January 1, 2012, and September 20, 2022.

resultsA total of 40 publications were included, with clinical, humanistic, and economic outcomes reported in 39, 5, and 15, respectively. Risk of influenza-associated clinical outcomes were reported to increase with age among the 18-64 years population, including hospitalizations (Yamana et al. in Intern Med 60:3401-3408, 2021; Derqui et al. in Influenza Other Respir Viruses 16:862-872, 2022; Fuller et al. in Influenza Other Respir Viruses 16:265-275, 2022; Ortiz et al. in Crit Care Med 42:2325-2332, 2014; Yandrapalli et al. in Ann Transl Med 6:318, 2018; Zimmerman et al. in Influenza Other Respir Viruses 16:1133-1140, 2022). ICU admissions, mortality, ER/outpatient visits, and use of mechanical ventilation were recorded. Adults aged 18-64 years with underlying comorbidities were at higher risk of influenza-related hospitalizations, ICU admission, and mortality than otherwise healthy individuals. Length of hospital stay increased with age, although a lack of stratification across other economic outcomes prevented identification of further trends across age groups.

conclusionsHigh levels of hospitalization and outpatient visits demonstrated a clinical influenza-associated burden on patients and healthcare systems, which is exacerbated by comorbidities. Considering the size and breadth of the general population aged 18-64 years, the limited humanistic and economic findings of this SLR likely reflect an underreported burden. Greater investigation into indirect costs and prolonged absenteeism associated with influenza infection is required to fully understand the economic burden in this population.

Indexed as

Influenza, HumanInfluenza VaccinesAgedCost of IllnessDelivery of Health CareHealth StatusHospitalizationHumansInfluenza VaccinesBurden of diseaseHCRUHospitalizationInfluenzaInfluenza vaccinationMortalitymRNA vaccineWorking population

Identifiers

PMID37470942
PMCPMC10499696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.